Biofrontera (NASDAQ:BFRI) Earns “Buy” Rating from Benchmark

Benchmark reiterated their buy rating on shares of Biofrontera (NASDAQ:BFRI) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

Biofrontera Trading Up 4.1 %

Shares of BFRI stock opened at $0.73 on Friday. The business’s 50 day simple moving average is $1.02 and its 200 day simple moving average is $1.09. Biofrontera has a one year low of $0.61 and a one year high of $4.04.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.